Catheter Precision's LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026
MWN-AI** Summary
Catheter Precision, Inc. (NYSE American: VTAK) is set to showcase its innovative LockeT suture retention device during live procedural cases at the International Symposium of Left Atrial Appendage (ISLAA) 2026, scheduled for March 5-6 in Los Angeles. This event, jointly organized by the Academy for Continued Healthcare Learning (ACHL) and ISLAA Foundation, focuses on advancements in the field of left atrial appendage (LAA) science and features notable institutions, including the Mayo Clinic and Mt. Sinai.
The LockeT device is designed to aid wound closure following percutaneous venous punctures, streamlining procedures and enhancing patient recovery times. Registered as a Class 1 device with the FDA and having received CE Mark approval, LockeT emphasizes both cost-effectiveness for hospitals and the potential for same-day patient discharge. During the ISLAA event, Catheter Precision will provide hands-on demonstrations, allowing electrophysiology fellows an opportunity to engage with LockeT directly, ask questions, and appreciate its practical benefits in real clinical settings.
David Jenkins, CEO of Catheter Precision, expressed pride in LockeT's growing recognition at significant industry gatherings, highlighting a recent appearance at the Structural Heart Intervention and Imaging 2026 conference. He noted the critical value of live cases in allowing physicians to validate the device's efficiency.
This announcement reinforces Catheter Precision's commitment to advancing medical technology in cardiac electrophysiology, collaborating with healthcare professionals to continuously enhance their innovative product offerings. As they prepare for the ISLAA 2026, the company emphasizes the potential impacts of LockeT on improving patient care and operational efficiency in cardiovascular procedures.
MWN-AI** Analysis
Catheter Precision, Inc. (NYSE American: VTAK) is positioned to capitalize on key advancements in the cardiac electrophysiology market, particularly with its innovative LockeT suture retention device being featured at the International Symposium of Left Atrial Appendage (ISLAA) 2026. This conference, which attracts leading physicians and industry professionals, will serve as a critical platform for demonstrating the efficacy and value of LockeT in real-world clinical scenarios.
LockeT, a Class 1 FDA-registered device with CE Mark approval, offers significant benefits, such as cost reductions for hospitals and facilitating same-day patient discharge. The device’s presence in live procedural cases allows for direct engagement with electrophysiology fellows, providing them hands-on experience and education about its advantages. The participation of Catheter Precision in these high-profile events underscores the company’s commitment to advancing medical technology while fostering medical education.
From a market perspective, Catheter Precision is poised for growth as the demand for efficiency in healthcare procedures continues to rise. With healthcare facilities under pressure to reduce costs and improve patient outcomes, the LockeT device presents a compelling proposition. The positive feedback from live demonstrations at prestigious conferences could lead to increased adoption among hospitals, driving revenue growth. Investors should closely monitor the reception of LockeT by hospital staff, as well as any future purchase orders, which could serve as indicators of market acceptance.
Additionally, it’s crucial to consider potential risks. Catheter Precision’s forward-looking statements highlight uncertainties that could affect the company’s trajectory. Investors should stay informed about the broader regulatory and market environment, as these can impact product evaluations and sales.
In summary, Catheter Precision, with its strategic focus on innovation and education, is well-positioned to leverage the market potential of the LockeT device. Investors may find opportunities for growth in this promising sector of medical technology, particularly as the company expands its product offerings and market presence.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the International Symposium of Left Atrial Appendage 2026 conference. The event, co-hosted by the Academy for Continued Healthcare Learning (ACHL) and ISLAA Foundation, will take place from March 5-6, 2026, at the Biltmore Hotel in Los Angeles, California.
The ISLAA meeting is a multi-specialty cardiovascular educational symposium on the frontier science of left atrial appendage (LAA). Over two days, course directors and leading physicians from The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo Clinic and Mt. Sinai will manage the program and content.
In addition, the ISLAA meeting provides a unique opportunity for hands-on demonstrations and product education for electrophysiology fellows. Catheter Precision will be participating in these sessions to provide fellows an opportunity to try LockeT, ask questions and learn more about the products benefits, which include cost reduction for the hospital and same day hospital discharge.
“We are proud that LockeT continues to gain traction at the industry's most prestigious gatherings,” said David Jenkins, CEO of Catheter Precision. “Our recent feature at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference underscores the importance of live clinical cases. They offer an unmatched opportunity for physicians to validate the efficiency and cost-effectiveness of our suture retention solutions in a real-world setting.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ**
What specific feedback do healthcare professionals provide about the performance and benefits of the LockeT suture retention device during the live procedural cases at the ISLAA 2026 conference organized by Catheter Precision Inc. VTAK?
How does Catheter Precision Inc. VTAK plan to leverage the momentum from the International Symposium of Left Atrial Appendage 20to enhance market adoption of the LockeT device?
In what ways does Catheter Precision Inc. VTAK expect the cost-reduction benefits of the LockeT device to impact hospital purchasing decisions and patient outcomes post-procedure?
What strategies does Catheter Precision Inc. VTAK have in place to address potential risks and uncertainties related to the adoption of the LockeT device, as outlined in their forward-looking statements?
**MWN-AI FAQ is based on asking OpenAI questions about Catheter Precision Inc. (NYSE: VTAK).
NASDAQ: VTAK
VTAK Trading
-14.71% G/L:
$1.6101 Last:
1,136,984 Volume:
$1.75 Open:
